ATE502650T1 - Verfahren zur befestigung von effektor-molekülen an proteinen - Google Patents

Verfahren zur befestigung von effektor-molekülen an proteinen

Info

Publication number
ATE502650T1
ATE502650T1 AT06744294T AT06744294T ATE502650T1 AT E502650 T1 ATE502650 T1 AT E502650T1 AT 06744294 T AT06744294 T AT 06744294T AT 06744294 T AT06744294 T AT 06744294T AT E502650 T1 ATE502650 T1 AT E502650T1
Authority
AT
Austria
Prior art keywords
protein
effector molecules
proteins
attaching
cysteines
Prior art date
Application number
AT06744294T
Other languages
English (en)
Inventor
Sam Philip Heywood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE502650T1 publication Critical patent/ATE502650T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Catalysts (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT06744294T 2005-07-06 2006-06-29 Verfahren zur befestigung von effektor-molekülen an proteinen ATE502650T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0513852.4A GB0513852D0 (en) 2005-07-06 2005-07-06 Biological products
PCT/GB2006/002416 WO2007003898A1 (en) 2005-07-06 2006-06-29 Process for attaching effector molecules to proteins

Publications (1)

Publication Number Publication Date
ATE502650T1 true ATE502650T1 (de) 2011-04-15

Family

ID=34856761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744294T ATE502650T1 (de) 2005-07-06 2006-06-29 Verfahren zur befestigung von effektor-molekülen an proteinen

Country Status (15)

Country Link
US (1) US8378073B2 (de)
EP (1) EP1912673B1 (de)
JP (1) JP5203188B2 (de)
CN (1) CN101212984B (de)
AT (1) ATE502650T1 (de)
AU (1) AU2006264684B2 (de)
CA (1) CA2613481C (de)
DE (1) DE602006020878D1 (de)
DK (1) DK1912673T3 (de)
ES (1) ES2361096T3 (de)
GB (1) GB0513852D0 (de)
PL (1) PL1912673T3 (de)
PT (1) PT1912673E (de)
SI (1) SI1912673T1 (de)
WO (1) WO2007003898A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009205995B2 (en) * 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
HUE042114T2 (hu) 2009-02-17 2019-06-28 Ucb Biopharma Sprl Humán OX40-re specifikus ellenanyag-molekulák
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
US9623188B2 (en) 2011-07-07 2017-04-18 Novo Nordisk A/S Drug delivery injection pen with add-on dose capturing and display module
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
ES2869309T3 (es) 2013-12-13 2021-10-25 Novo Nordisk Healthcare Ag Método para la conjugación de proteínas con tioéter
CA3211226A1 (en) * 2014-02-11 2015-08-20 Seagen Inc. Selective reduction of proteins
GB201419184D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
IL252712B2 (en) * 2014-12-22 2024-04-01 UCB Biopharma SRL Method for protein production
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CN107708679A (zh) 2015-06-04 2018-02-16 安特里阿比奥有限公司 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法
KR102322530B1 (ko) * 2017-02-08 2021-11-05 화이자 인코포레이티드 캡핑된 및 비-캡핑된 항체 시스테인의 대규모 제조 공정 및 치료 단백질 접합에서의 그의 용도
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022122652A1 (en) 2020-12-07 2022-06-16 UCB Biopharma SRL Antibodies against interleukin-22
BR112023022844A2 (pt) 2021-05-03 2024-01-23 UCB Biopharma SRL Anticorpos
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728430A (en) * 1986-02-10 1988-03-01 Millipore Corporation Diafiltration method
US5216183A (en) * 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
US5225194A (en) * 1989-11-13 1993-07-06 Ldc Research Corporation Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases
AU1140495A (en) 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
DE69934248T2 (de) * 1998-10-30 2007-03-29 Nephros, Inc. Anlage zur nicht-isosmotischen diafiltration
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6406631B1 (en) * 1999-07-30 2002-06-18 Nephros, Inc. Two stage diafiltration method and apparatus
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CN1621091A (zh) * 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7908694B1 (en) * 2008-09-24 2011-03-22 Robert Sloane Mattress cover apparatus with integrated seals

Also Published As

Publication number Publication date
US20080306246A1 (en) 2008-12-11
CN101212984A (zh) 2008-07-02
CA2613481C (en) 2014-11-25
AU2006264684B2 (en) 2011-11-03
US8378073B2 (en) 2013-02-19
WO2007003898A1 (en) 2007-01-11
EP1912673A1 (de) 2008-04-23
AU2006264684A1 (en) 2007-01-11
PT1912673E (pt) 2011-04-14
PL1912673T3 (pl) 2011-07-29
JP2008544976A (ja) 2008-12-11
DE602006020878D1 (de) 2011-05-05
SI1912673T1 (sl) 2011-10-28
CN101212984B (zh) 2011-09-28
CA2613481A1 (en) 2007-01-11
GB0513852D0 (en) 2005-08-10
ES2361096T3 (es) 2011-06-13
JP5203188B2 (ja) 2013-06-05
DK1912673T3 (da) 2011-05-02
EP1912673B1 (de) 2011-03-23
WO2007003898A8 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
ATE502650T1 (de) Verfahren zur befestigung von effektor-molekülen an proteinen
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
WO2009052396A3 (en) Novel process for solubilizing protein from a proteinaceous material and compositions thereof
DE602006014846D1 (de) Verfahren zur quantifizierung von allergenen
DE602006017918D1 (de) Verfahren zur Herstellung von Telmisartan
DE602007008126D1 (de) Verfahren zur herstellung von (s)-4-fluormethyldihydrofuran-2-on
DE602006007612D1 (de) Verfahren und zwischenprodukte zur synthese des caspofungins
DE502006006803D1 (de) Verfahren zur herstellung von leder
DE602006019870D1 (de) Verfahren zur synthese von triazolen
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
ATE446941T1 (de) Verfahren zur gekoppelten herstellung von chlor und isocyanaten
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren
EA200701852A1 (ru) Производные аминокислот
DE602006021124D1 (de) Verfahren zur Herstellung von Gummibestandteilen für Luftreifen
DE602005025002D1 (de) Verfahren zur herstellung von brenztraubensäure
DE602006003769D1 (de) Verfahren zur herstellung von 4-amino-4'-demethyl-4-desoxypodophylotoxin
BRPI0608020A2 (pt) processo para a produção de uma composição contendo proteìna de soja e composição contendo proteìna de soja
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
DE60322852D1 (de) Verfahren zur herstellung von eplerenon
DE602005013993D1 (de) Verfahren zur herstellung von 2-hydroxy-4-(methylthio)butansäure
ATE400574T1 (de) Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase
ITRM20050425A1 (it) Processo per la produzione di prodotti a base di idrolizzati proteici in composizione con manganese.
ATE389644T1 (de) Verfahren zur destillativen aufarbeitung von tetrahydrofuran
ATE405554T1 (de) Verfahren zur herstellung von pramipexole

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912673

Country of ref document: EP